Global Active Pharmaceutical Ingredients CDMO Market Size (2024 - 2029)

The API CDMO market is projected to experience significant growth during the forecast period, driven by increased pharmaceutical R&D investments and a rising demand for generic drugs due to the growing prevalence of chronic diseases. The expansion of API manufacturing capabilities by market players further contributes to this growth. However, challenges such as compliance issues and concerns about data quality and security may impact the market's expansion.

Market Size of Global Active Pharmaceutical Ingredients CDMO Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Active Pharmaceutical Ingredients CDMO Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 118.09 Billion
Market Size (2029) USD 178.47 Billion
CAGR (2024 - 2029) 8.61 %
Fastest Growing Market Asia-Pacific
Largest Market Asia-Pacific

Major Players

Active Pharmaceutical Ingredients CDMO Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Active Pharmaceutical Ingredients CDMO Market Analysis

The Global Active Pharmaceutical Ingredients CDMO Market size is estimated at USD 118.09 billion in 2024, and is expected to reach USD 178.47 billion by 2029, growing at a CAGR of 8.61% during the forecast period (2024-2029).

Various factors, such as increasing pharmaceutical research and development investment, rising demands for generic drugs, complex manufacturing, and patent expiration, will lead to market growth during the forecast period.

The increase in pharmaceutical research and development (R&D) investment is one of the factors significantly driving the market growth. The rise in pharmaceutical R&D investment is expected to fuel the adoption of active pharmaceutical ingredient (API) contract development and manufacturing organizations (CDMO) to develop APIs. For instance, the report published by the European Federation of Pharmaceutical Industry and Associations in June 2023 highlighted that pharmaceutical companies invested USD 49,112 million in R&D in Europe in 2022. Additionally, the same source reported that the R&D investments were majorly allocated to clinical trials (49.2%), followed by pre-clinical functions (14.7%) and pharmacovigilance (12.9%). Thus, significant investments by pharmaceutical companies are the primary factors expected to boost the market during the forecast period.

In addition, the increasing demand for generic drugs due to the growing burden of chronic diseases contributes significantly to the market growth. Generic drugs are used to treat complicated chronic disorders like cancers, cardiovascular disorders, neurological disorders, and infections. For instance, an article published by the National Institutes of Health in July 2023 mentioned that about 10.5 million people had dementia in 2022, which is expected to increase to 18.7 million in 2050. Moreover, according to 2023 updated data published by the International Diabetes Federation, diabetic patients are expected to reach 643 million and 784 million globally by 2030 and 2045, respectively. Thus, the increase in chronic disease prevalence is anticipated to fuel the demand for generic drugs, further strengthening the market growth of API CDMO during the forecast period.

The market players have adopted various strategies to expand API manufacturing, further boosting market growth. For instance, in December 2022, Novasep invested approximately USD 6.3 million (EUR 6 million) to enhance its Chasse-sur-Rhône facility in France. The investment focused on improving the site's capabilities in handling advanced APIs related to specialized medical fields, including oncology, central nervous system (CNS) disorders, and infectious diseases. Additionally, in May 2022, Piramal Pharma Solutions stated that the company's new active pharmaceutical ingredient (API) plant in Aurora, Ontario, went online and completed its initial production runs. Thus, such initiatives are anticipated to drive the API CDMO market growth during the forecast period.

Hence, increasing R&D investments and rising demand for generic drugs due to the growing burden of chronic diseases among patients are the major factors driving the market growth. However, compliance issues while outsourcing and concerns about data quality and security are expected to affect the market growth of API CDMO during the forecast period.

Active Pharmaceutical Ingredients CDMO Industry Segmentation

As per the scope of this report, an active pharmaceutical ingredient (API) is the part of the drug that produces the intended effects. It is the biologically active component of a drug product, such as a capsule, tablet, injectable, or cream. Traditionally, pharmaceutical companies would produce APIs. However, in recent years, many companies have opted to outsource the production of API, as most companies have realized that the returns on investments have been worthwhile. With the right outsourcing partner, the advantages outweigh the potential risks.

The active pharmaceutical ingredients CDMO market is segmented by molecule type, synthesis, drug type, workflow, application, and geography. By molecule type, the market is segmented into small and large molecules. By synthesis, the market is segmented into biotech and synthetic. By drug type, the market is segmented into innovative and generics. By workflow, the market is segmented into clinical and commercial. The market is segmented by application into cardiology, oncology, ophthalmology, neurology, orthopedic, and other applications. The market is segmented by geography into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. For each segment, the market size is provided in terms of USD value.

By Molecule Type
Small Molecule
Large Molecule
By Synthesis
Biotech
Synthetic
By Drug Type
Innovative
Generics
By Workflow
Clinical
Commercial
By Application
Cardiology
Oncology
Ophthalmology
Neurology
Orthopedic
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Active Pharmaceutical Ingredients CDMO Market Size Summary

The API CDMO market is poised for significant growth, driven by increasing investments in pharmaceutical research and development, the rising demand for generic drugs, and the complexities of modern drug manufacturing. The market is expected to expand substantially over the forecast period, with strategic initiatives by key players further propelling its growth. The demand for active pharmaceutical ingredients is bolstered by the growing prevalence of chronic diseases, necessitating the development and production of effective pharmaceuticals. This has led to a surge in the adoption of API CDMO services, as pharmaceutical companies seek to enhance their manufacturing capabilities and meet the evolving needs of the market.

Regionally, Asia-Pacific is anticipated to be a major contributor to the market's expansion, supported by substantial investments in pharmaceutical production and favorable government initiatives. Countries like India are playing a pivotal role, with initiatives such as the Production Linked Incentive scheme boosting API manufacturing. The market landscape is characterized by a mix of established players and emerging companies, all vying to capture market share through strategic expansions, collaborations, and investments. As the industry continues to evolve, the API CDMO market is set to experience robust growth, driven by both demand-side factors and strategic actions by market participants.

Explore More

Global Active Pharmaceutical Ingredients CDMO Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Pharmaceutical R&D Investment

      2. 1.2.2 Rising Demand for Generic Drugs

      3. 1.2.3 Complex Manufacturing

      4. 1.2.4 Patent Expiration

    3. 1.3 Market Restraints

      1. 1.3.1 Compliance Issues while Outsourcing

      2. 1.3.2 Concerns about Data Quality and Security

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Molecule Type

      1. 2.1.1 Small Molecule

      2. 2.1.2 Large Molecule

    2. 2.2 By Synthesis

      1. 2.2.1 Biotech

      2. 2.2.2 Synthetic

    3. 2.3 By Drug Type

      1. 2.3.1 Innovative

      2. 2.3.2 Generics

    4. 2.4 By Workflow

      1. 2.4.1 Clinical

      2. 2.4.2 Commercial

    5. 2.5 By Application

      1. 2.5.1 Cardiology

      2. 2.5.2 Oncology

      3. 2.5.3 Ophthalmology

      4. 2.5.4 Neurology

      5. 2.5.5 Orthopedic

      6. 2.5.6 Other Applications

    6. 2.6 Geography

      1. 2.6.1 North America

        1. 2.6.1.1 United States

        2. 2.6.1.2 Canada

        3. 2.6.1.3 Mexico

      2. 2.6.2 Europe

        1. 2.6.2.1 Germany

        2. 2.6.2.2 United Kingdom

        3. 2.6.2.3 France

        4. 2.6.2.4 Italy

        5. 2.6.2.5 Spain

        6. 2.6.2.6 Rest of Europe

      3. 2.6.3 Asia-Pacific

        1. 2.6.3.1 China

        2. 2.6.3.2 Japan

        3. 2.6.3.3 India

        4. 2.6.3.4 Australia

        5. 2.6.3.5 South Korea

        6. 2.6.3.6 Rest of Asia-Pacific

      4. 2.6.4 Middle East and Africa

        1. 2.6.4.1 GCC

        2. 2.6.4.2 South Africa

        3. 2.6.4.3 Rest of Middle East and Africa

      5. 2.6.5 South America

        1. 2.6.5.1 Brazil

        2. 2.6.5.2 Argentina

        3. 2.6.5.3 Rest of South America

Global Active Pharmaceutical Ingredients CDMO Market Size FAQs

The Global Active Pharmaceutical Ingredients CDMO Market size is expected to reach USD 118.09 billion in 2024 and grow at a CAGR of 8.61% to reach USD 178.47 billion by 2029.

In 2024, the Global Active Pharmaceutical Ingredients CDMO Market size is expected to reach USD 118.09 billion.

API CDMO Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)